Limits...
Metabolomics: a novel approach to early and noninvasive prostate cancer detection.

Roberts MJ, Schirra HJ, Lavin MF, Gardiner RA - Korean J Urol (2011)

Bottom Line: Application of metabolomics to biofluids and in vivo quantification as well as the direction of current research in supplementing and improving current methods of detection are discussed.The current debate in the urology literature on sarcosine as a potential biomarker for PCa is reviewed and discussed.Metabolomics promises to be a valuable tool in the early detection of PCa that may enable earlier treatment and improved clinical outcomes.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, University of Queensland Centre for Clinical Research, Brisbane, Australia.

ABSTRACT
Prostate cancer (PCa) is the most commonly diagnosed visceral cancer in men and is responsible for the second highest cancer-related male mortality rate in Western countries, with increasing rates being reported in Korea, Japan, and China. Considering the low sensitivity of prostate-specific antigen (PSA) testing, it is widely agreed that reliable, age-independent markers of the presence, nature, and progression of PCa are required to facilitate diagnosis and timely treatment. Metabolomics or metabonomics has recently emerged as a novel method of PCa detection owing to its ability to monitor changes in the metabolic signature, within biofluids or tissue, that reflect changes in phenotype and function. This review outlines the physiology of prostate tissue and prostatic fluid in health and in malignancy in relation to metabolomics as well as the principles underlying the methods of metabolomic quantification. Promising metabolites, metabolic profiles, and their correlation with the presence and stage of PCa are summarized. Application of metabolomics to biofluids and in vivo quantification as well as the direction of current research in supplementing and improving current methods of detection are discussed. The current debate in the urology literature on sarcosine as a potential biomarker for PCa is reviewed and discussed. Metabolomics promises to be a valuable tool in the early detection of PCa that may enable earlier treatment and improved clinical outcomes.

No MeSH data available.


Related in: MedlinePlus

Summary of targets in the 'omic' era of analysis. The hierarchical levels of cellular organization involved in the progression from genotype to phenotype are shown. This expression of cellular phenotype is tightly regulated by feedback mechanisms, as shown above the progression. Through this process, various targets are available for analysis and opportunistic manipulation, as shown below the progression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3045724&req=5

Figure 1: Summary of targets in the 'omic' era of analysis. The hierarchical levels of cellular organization involved in the progression from genotype to phenotype are shown. This expression of cellular phenotype is tightly regulated by feedback mechanisms, as shown above the progression. Through this process, various targets are available for analysis and opportunistic manipulation, as shown below the progression.

Mentions: Metabolomics can detect and quantify low-molecular-weight metabolites produced by living cells [5]. Metabolomics has been described as "the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification" [23]. The metabolites of living cells are seen as the end products of the biological hierarchy starting with activated genes (genome) and extending over the collection of gene transcripts (transcriptome) and proteins (proteome). This process is summarized in Fig. 1.


Metabolomics: a novel approach to early and noninvasive prostate cancer detection.

Roberts MJ, Schirra HJ, Lavin MF, Gardiner RA - Korean J Urol (2011)

Summary of targets in the 'omic' era of analysis. The hierarchical levels of cellular organization involved in the progression from genotype to phenotype are shown. This expression of cellular phenotype is tightly regulated by feedback mechanisms, as shown above the progression. Through this process, various targets are available for analysis and opportunistic manipulation, as shown below the progression.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3045724&req=5

Figure 1: Summary of targets in the 'omic' era of analysis. The hierarchical levels of cellular organization involved in the progression from genotype to phenotype are shown. This expression of cellular phenotype is tightly regulated by feedback mechanisms, as shown above the progression. Through this process, various targets are available for analysis and opportunistic manipulation, as shown below the progression.
Mentions: Metabolomics can detect and quantify low-molecular-weight metabolites produced by living cells [5]. Metabolomics has been described as "the quantitative measurement of the dynamic multiparametric metabolic response of living systems to pathophysiological stimuli or genetic modification" [23]. The metabolites of living cells are seen as the end products of the biological hierarchy starting with activated genes (genome) and extending over the collection of gene transcripts (transcriptome) and proteins (proteome). This process is summarized in Fig. 1.

Bottom Line: Application of metabolomics to biofluids and in vivo quantification as well as the direction of current research in supplementing and improving current methods of detection are discussed.The current debate in the urology literature on sarcosine as a potential biomarker for PCa is reviewed and discussed.Metabolomics promises to be a valuable tool in the early detection of PCa that may enable earlier treatment and improved clinical outcomes.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, University of Queensland Centre for Clinical Research, Brisbane, Australia.

ABSTRACT
Prostate cancer (PCa) is the most commonly diagnosed visceral cancer in men and is responsible for the second highest cancer-related male mortality rate in Western countries, with increasing rates being reported in Korea, Japan, and China. Considering the low sensitivity of prostate-specific antigen (PSA) testing, it is widely agreed that reliable, age-independent markers of the presence, nature, and progression of PCa are required to facilitate diagnosis and timely treatment. Metabolomics or metabonomics has recently emerged as a novel method of PCa detection owing to its ability to monitor changes in the metabolic signature, within biofluids or tissue, that reflect changes in phenotype and function. This review outlines the physiology of prostate tissue and prostatic fluid in health and in malignancy in relation to metabolomics as well as the principles underlying the methods of metabolomic quantification. Promising metabolites, metabolic profiles, and their correlation with the presence and stage of PCa are summarized. Application of metabolomics to biofluids and in vivo quantification as well as the direction of current research in supplementing and improving current methods of detection are discussed. The current debate in the urology literature on sarcosine as a potential biomarker for PCa is reviewed and discussed. Metabolomics promises to be a valuable tool in the early detection of PCa that may enable earlier treatment and improved clinical outcomes.

No MeSH data available.


Related in: MedlinePlus